Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Syndax Pharma (SNDX)

Syndax Pharma (SNDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Syndax Pharmaceuticals Announces Plans to Commence Phase 2 Expansion Cohort of SNDX-6352 for the Treatment of Chronic Graft Versus Host Disease

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it...

SNDX : 8.73 (+0.46%)
Syndax Announces Preclinical Results Supporting Development of its Portfolio of Menin Inhibitors In Mixed Lineage Leukemias

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the publication...

SNDX : 8.73 (+0.46%)
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Misses Revenue Estimates

Syndax (SNDX) delivered earnings and revenue surprises of 14.58% and -0.26%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

SNDX : 8.73 (+0.46%)
Syndax Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Business Update

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial...

SNDX : 8.73 (+0.46%)
Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the...

SNDX : 8.73 (+0.46%)
Syndax to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 7, 2019

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will...

SNDX : 8.73 (+0.46%)
JDRF T1D Fund Appoints Veteran Life Sciences Executive Dr. Steven St. Peter as Managing Director

The JDRF T1D Fund, the venture philanthropy fund focused on accelerating life-changing solutions to cure, prevent, and treat type 1 diabetes (T1D) through catalytic investments, today announced the expansion...

PETX : 4.92 (-0.20%)
RYTM : 25.50 (+2.60%)
SNDX : 8.73 (+0.46%)
PRTO : 0.32 (+5.33%)
Implied Volatility Surging for Syndax (SNDX) Stock Options

Investors need to pay close attention to Syndax (SNDX) stock based on the movements in the options market lately.

SNDX : 8.73 (+0.46%)
Syndax Announces Participation at Four Upcoming Investor Conferences

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members...

SNDX : 8.73 (+0.46%)
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates

Syndax (SNDX) delivered earnings and revenue surprises of -6.82% and -2.82%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

SNDX : 8.73 (+0.46%)
Syndax Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Clinical and Business Update

Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the second quarter...

SNDX : 8.73 (+0.46%)
Syndax to Participate in the BTIG Biotechnology Conference

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs...

SNDX : 8.73 (+0.46%)
Syndax to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 7, 2019

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will...

SNDX : 8.73 (+0.46%)
Syndax Pharmaceuticals Announces FDA Clearance of IND Application for Targeted Menin Inhibitor SNDX-5613 for Relapsed/Refractory Acute Leukemias

Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Food and Drug Administration...

SNDX : 8.73 (+0.46%)
Syndax to Present at the UBS Global Healthcare Conference

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs...

SNDX : 8.73 (+0.46%)
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates

Syndax (SNDX) delivered earnings and revenue surprises of 5.36% and -0.26%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

SNDX : 8.73 (+0.46%)
Syndax Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Clinical and Business Update

Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the first quarter...

SNDX : 8.73 (+0.46%)
Syndax to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 6, 2019

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it...

SNDX : 8.73 (+0.46%)
Research Report Identifies Chimerix, Evolent Health, ABIOMED, Syndax Pharmaceuticals, Independence Realty Trust, and Selecta Biosciences with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Chimerix, Inc. (NASDAQ:CMRX),...

CMRX : 2.02 (-20.16%)
EVH : 9.10 (+1.22%)
ABMD : 179.75 (-1.07%)
SNDX : 8.73 (+0.46%)
IRT : 14.74 (-0.47%)
SELB : 1.65 (+5.77%)
Syndax Pharmaceuticals Presents Updated Phase 2 Data from ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2019 Annual Meeting

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the presentation...

MRK : 89.50 (+0.45%)
SNDX : 8.73 (+0.46%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI +0.50 , AIZ -0.89 , SBAC -2.15 , SO -1.11 , WELL -0.45
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar